Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)

a study on Myasthenia Gravis

Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at Irvine, California and other locations
Dates
study started
completion around

Description

Summary

This is a Phase IIb study to evaluate the safety and preliminary efficacy of Descartes-08 CAR T-cells in patients with Generalized Myasthenia Gravis

Official Title

Autologous T-Cells Expressing A Chimeric Antigen Receptor Directed To B-Cell Maturation Antigen (BCMA) In Patients With Generalized Myasthenia Gravis (MG)

Keywords

Myasthenia Gravis, Generalized, Descartes-08, CART, CAR-T, Autoimmune, Auto-antibody, Auto antibody, chimeric antigen receptor, T cells, MG, gMG, Myasthenia Gravis, Generalized Myasthenia gravis, Muscle Weakness

Eligibility

You can join if…

Open to people ages 18 years and up

  • Patient must be at least 18 years of age.
  • Patient must have Generalized Myasthenia Gravis at the time of screening.
  • Concomitant immunosuppressive drugs must be deemed necessary by the investigator.
  • Seronegative Patients are included

You CAN'T join if...

  • Major chronic illness that is not well managed at the time of study entry and in the opinion of the investigator may increase the risk to the patient.
  • Patient is pregnant or lactating.

Locations

  • University of California Irvine accepting new patients
    Irvine California 92697 United States
  • Profound Research accepting new patients
    Carlsbad California 92011 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Cartesian Therapeutics
ID
NCT04146051
Phase
Phase 2 Myasthenia Gravis Research Study
Study Type
Interventional
Participants
Expecting 30 study participants
Last Updated
Contact us about this trial